Centiva Capital LP Sells 7,458 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Centiva Capital LP trimmed its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,490 shares of the company’s stock after selling 7,458 shares during the period. Centiva Capital LP’s holdings in Harmony Biosciences were worth $900,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in Harmony Biosciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,219 shares of the company’s stock valued at $478,000 after purchasing an additional 1,201 shares during the period. SG Americas Securities LLC bought a new stake in shares of Harmony Biosciences in the second quarter valued at approximately $138,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Harmony Biosciences by 214.1% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 44,945 shares of the company’s stock worth $1,356,000 after acquiring an additional 30,638 shares during the last quarter. Summit Global Investments increased its position in Harmony Biosciences by 4.2% during the second quarter. Summit Global Investments now owns 20,164 shares of the company’s stock worth $608,000 after acquiring an additional 807 shares during the period. Finally, nVerses Capital LLC acquired a new position in Harmony Biosciences during the 2nd quarter valued at $36,000. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $33.49 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock’s fifty day simple moving average is $34.85 and its 200 day simple moving average is $33.83. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 15.87, a P/E/G ratio of 0.64 and a beta of 0.79.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the firm posted $0.63 EPS. On average, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current fiscal year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 30.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HRMY. UBS Group initiated coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target on the stock. Cantor Fitzgerald boosted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Mizuho upped their price target on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a report on Tuesday, October 29th. Finally, Raymond James restated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $47.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.